ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.
![](https://agendia.com/wp-content/uploads/2020/11/subnav-bigimage4-3.png)
What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
News
Media Releases
BluePrint® Identifies Genomic Subtypes for African-American Breast Cancer Patients with Low Risk Outcomes
PRESS RELEASE New data presented at ASCO underscores importance of genomic profiling for African-American women with breast cancer whose unique tumor biology can sometimes lead to poorer prognoses IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS Read More
Agendia Appoints Two Industry Veterans to Board of Directors
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 31 May 2019 – Agendia, Inc., a world leader in precision oncology, announced today the appointment of industry veterans Laurie Heilmann and François Ferré, Ph.D. to Read More
Agendia and Imegen Announce an Exclusive Distribution Agreement for MammaPrint® and BluePrint® in Spain and Portugal
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 21 May 2019 – Agendia, Inc., a world leader in precision oncology, announced today an agreement with Imegen (Valencia, Spain), for the exclusive distribution of the Read More
New Data Show BluePrint® Identifies Estrogen Receptor Positive Breast Cancer Patients With Poor Response To Anti-Estrogen Therapy Who May Benefit From Neoadjuvant Chemotherapy
PRESS RELEASE ER+ breast cancer patients reclassified as ER+ basal-type demonstrated significant response to chemotherapy underscoring critical role of advanced diagnostic tools Results published in Nature Publishing Group’s npj Breast Cancer IRVINE, CALIF., U.S., and Read More